Acumen Pharmaceuticals to report Q1 2026 financial results on May 12 with a live webcast.

Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company focused on Alzheimer's disease treatments, will announce its first quarter 2026 financial results on May 12, 2026. The company will hold a conference call and live webcast at 8:00 a.m. ET to provide updates on its business and financial status. Acumen is advancing its lead drug candidate, sabirnetug (ACU193), in a Phase 2 trial for early Alzheimer's, following promising Phase 1 results. Investors and interested parties can register to participate in the call or access the webcast via the company's website.